Cargando…

E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?

Detalles Bibliográficos
Autor principal:	Zhang, Liyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058311/ https://www.ncbi.nlm.nih.gov/pubmed/35352486 http://dx.doi.org/10.1111/1759-7714.14399

Ejemplares similares

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
por: Yeruva, Sri Lakshmi Hyndavi, et al.
Publicado: (2018)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

The Beginning of the End—The Knell of Sectarianism in Medicine
por: Rochester, DeLancey
Publicado: (1902)

Cheiloscopy in gender determination: A study on 2112 individuals
por: Thermadam, Tim Peter, et al.
Publicado: (2020)

2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes
por: Mourad, Ahmad, et al.
Publicado: (2019)

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis
por: Xu, Liang, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

The Role of Histone Deacetylase 3 Complex in Nuclear Hormone Receptor Action
por: Ishii, Sumiyasu
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Neddylation Regulates Class IIa and III Histone Deacetylases to Mediate Myoblast Differentiation
por: Zhou, Hongyi, et al.
Publicado: (2021)

Suppression of Esophageal Cancer Stem-like Cells by SNX-2112 Is Enhanced by STAT3 Silencing
por: Xu, Dan-dan, et al.
Publicado: (2020)

2112. Incidence and outcomes of infections in liver transplant recipients during the first year post-transplant.
por: Alpizar-Rivas, Rodolfo M, et al.
Publicado: (2022)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer
por: Di Fazio, Pietro, et al.
Publicado: (2016)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

2112. Assessing the Accuracy of Catheter-Associated Urinary Tract Infections (CAUTI) Identification Using Urinalysis Results
por: Pender, Sarah, et al.
Publicado: (2018)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

The class II histone deacetylase HDAC4 regulates cognitive, metabolic and endocrine functions through its expression in osteoblasts
por: Makinistoglu, Munevver Parla, et al.
Publicado: (2014)

Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis
por: Hamam, Hussein J., et al.
Publicado: (2019)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylases and Their Inhibition in Candida Species
por: Garnaud, Cécile, et al.
Publicado: (2016)

Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d7tvmgv52idpte9hfti4u755d1